MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
The STROLL Study
Nitinol self-expandable stent placement for the treatment of obstructive SFA disease.
By Andrew J. Feiring, MD, FACC, FSCAI
Treating BTK CLI With Balloon-Expandable DES After Retrograde Tibial-Popliteal Recanalization
By Andrew J. Feiring, MD, FACC, FSCAI; Andrew McGown, MD; Jason Boudreau, DPM; and Lori Nelson, NP
Below-the-Knee Drug-Eluting Stents
Is there a role for this readily available device in treating critical limb ischemia?
Ask the Experts:
What is your go-to option for treating in-stent restenosis?
With Antonio Micari, MD, PhD; Prof. Dr. med. Nicolas Diehm; Michael H. Wholey, MD, MBA; Jos C. van den Berg, MD, PhD; and Andrew J. Feiring, MD, FACC, FSCAI, FAHA
Balloon-Expandable DES for CLI Supported in PARADISE
April 6, 2010—In the Journal of the American College of Cardiology, Andrew J. Feiring, MD, et al published findings from the PARADISE (Preventing Amputations Using Drug-Eluting Stents) trial, which is an investigation of the efficacy and safety of using balloon-expandable, drug-eluting stents (DES) to prevent amputations in patients with below-the-knee critical limb ischemia (CLI) (2010;55:1580β1589). The background of the study is the recognition that CLI patients have a 1-year amputation rate of 30% and a mortality rate of 25%. Most patients with CLI have severe below-the-knee arterial disease that limits the use of bypass surgery or balloon angioplasty.
PARADISE Trial Supports Use of Balloon-Expandable DES to Treat CLI
April 6, 2010βIn the Journal of the American College of Cardiology, Andrew J. Feiring, MD, et al published findings from the PARADISE (Preventing Amputations Using Drug-Eluting Stents) trial, which is an investigation of the efficacy and safety of using balloon-expandable, drug-eluting stents (DES) to prevent amputations in patients with below-the-knee critical limb ischemia (CLI) (2010;55:1580β1589). The background of the study is the recognition that CLI patients have a 1-year amputation rate of 30% and a mortality rate of 25%. Most patients with CLI have severe below-the-knee arterial disease that limits the use of bypass surgery or balloon angioplasty.
Progress in Amputation Prevention
By Jihad A. Mustapha, MD, FACC, FSCAI, Guest Chief Medical Editor
Preliminary Experience With DESs in Tibial Arteries
Sirolimus-eluting stents appear to be safe and effective in treating focal infrapopliteal obstructions.
By Dierk Scheinert, MD; Giancarlo Biamino, MD; and Andrej Schmidt, MD
